IGI Logo

Alembic Pharmaceuticals is currently trading at Rs. 1177.95, up by 18.20 points or 1.57% from its previous closing of Rs. 1159.75 on the BSE.

The scrip opened at Rs. 1160.05 and has touched a high and low of Rs. 1186.00 and Rs. 1160.05 respectively. So far 1003 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1296.15 on 09-Oct-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023.

Last one week high and low of the scrip stood at Rs. 1200.30 and Rs. 1117.00 respectively. The current market cap of the company is Rs. 22796.41 crore.

The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 19.99% and 10.40% respectively.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Dilacor XR Extended-Release Capsules, 120 mg, 180 mg, and 240 mg, of Allergan Sales LLC (Allergan). 

Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension. Diltiazem hydrochloride may be used alone or in combination with other antihypertensive medications, such as diuretics. It is also indicated for the management of chronic stable angina. Refer label for a detailed indication.

Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg have an estimated market size of $28.2 million for twelve months ending June 2024 according to IQVIA. Alembic has a cumulative total of 217 ANDA approvals (190 final approvals and 27 tentative approvals) from USFDA. 

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.